Clinical Trials Directory

Trials / Completed

CompletedNCT04842422

Earliest Stage Treatment of Aktinic Keratosis With Imiquimod 3.75% Cream

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
48 (actual)
Sponsor
Medical University of Graz · Academic / Other
Sex
Female
Age
50 Years
Healthy volunteers
Accepted

Summary

Earliest Stage Treatment of Actinic Keratosis with Imiquimod 3.75% Cream: The study is to demonstrate that Aktinic Keratosis are present before they are clinically visible, i.e. in a subclinical stage. Since on the basis of the research situation, also subclinical AK can proliferate into the dermis, it is possible that with the application of Imiquimod on chronically light-exposed skin, undetected squamous cell carcinoma can be recognized and treated at the same time.

Conditions

Interventions

TypeNameDescription
DRUGImiquimod 3.75% CreamImiquimod 3.75% Cream

Timeline

Start date
2021-04-16
Primary completion
2021-08-23
Completion
2021-08-23
First posted
2021-04-13
Last updated
2022-01-11

Locations

1 site across 1 country: Austria

Source: ClinicalTrials.gov record NCT04842422. Inclusion in this directory is not an endorsement.

Earliest Stage Treatment of Aktinic Keratosis With Imiquimod 3.75% Cream (NCT04842422) · Clinical Trials Directory